The first, approved for clinical use by the FDA on January 2014 for the treatment of metastatic B-Raf-driven melanoma, is a combination of Raf and Mek inhibitors (dabrafenib plus trametinib) [136]. This evidence concerns the gene BRAF and melanoma.